Mode
Text Size
Log in / Sign up

Individual participant data meta-analysis shows exercise-based cardiac rehabilitation reduces hospitalization, not mortality in coronary heart diseaseHeart Patients Stay Out of Hospital with Exercise

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note exercise-based cardiac rehabilitation reduces hospitalization in coronary heart disease; no mortality benefit.

This individual participant data meta-analysis evaluates the impact of exercise-based cardiac rehabilitation on individuals with coronary heart disease. The review included 4975 participants derived from 8 trials, selected from 30 eligible trials encompassing 10,677 participants. The population consisted of 93.5% post-myocardial infarction patients, with follow-up extending up to 12 months.

Results indicated a lower risk for all-cause hospitalization with an hazard ratio of 0.68 and a 95% confidence interval of 0.53, 0.87. Cardiovascular disease-related hospitalization also showed a lower risk, with a hazard ratio of 0.62 and a 95% confidence interval of 0.47, 0.83. Health-related quality of life was higher, showing a mean difference of 0.032 with a 95% confidence interval of 0.003, 0.061.

In contrast, all-cause mortality showed no difference, with a hazard ratio of 0.99 and a 95% confidence interval of 0.74, 1.32. Cardiovascular disease-related mortality similarly showed no difference, with a hazard ratio of 0.80 and a 95% confidence interval of 0.32, 2.04. Safety data regarding adverse events, serious adverse events, and discontinuations were not reported.

The authors note that subgroup analyses showed differential effects on health-related quality of life and hospitalization risk. This evidence supports the class I recommendation of international clinical guidelines that exercise-based cardiac rehabilitation should be offered to all people with coronary heart disease. Clinicians should interpret these findings within the context of the specific trial populations included in the analysis.

  • Exercise cuts hospital visits and boosts daily life.
  • Helps anyone with coronary heart disease.
  • Requires doctor approval before starting any plan.

New research confirms that moving your body helps heart patients stay out of the hospital.

Why heart patients hesitate to move

Imagine leaving the hospital after a heart scare. You feel relieved but also scared. Doctors tell you to rest. You worry that moving too much might hurt your heart.

Many people stay on the couch because of this fear. They think exercise is dangerous after a cardiac event. This hesitation is common and understandable.

The surprising shift in medical thinking

For years, doctors debated if exercise was safe. Some believed it might cause more harm than good. The medical community was unsure about the best advice.

But here is the twist. New data changes the conversation completely. We now have clear proof that movement is safe.

How exercise acts like medicine

Think of your heart like a car engine. If you leave it running too long without care, it gets stiff. Exercise keeps the engine running smoothly.

It strengthens the muscle and clears out blockages. It also helps your body manage stress better. This is why it feels like medicine.

Who benefits the most from rehab

The study looked at over 5,000 patients. They came from eight different research trials. All participants had coronary heart disease.

Most of them had already had a heart attack. The data covered modern treatment methods from 2010 onward. This makes the results very relevant today.

What doctors say about starting now

The results were clear and positive. Patients who did exercise-based rehab had fewer hospital visits. They also reported feeling much better in daily life.

This does not mean you should start running tomorrow.

Some groups saw even bigger benefits. People with lower heart pumping strength did well. Those with lower education levels also improved.

The study showed consistent results across most groups. It supports the idea that everyone should be offered this care.

What this means for your health

You might wonder if this applies to you. The study included people with various health backgrounds. It suggests the benefits are broad and reliable.

However, you should not start without guidance. Your heart condition is unique to you. Safety comes first.

No study is perfect. This research focused on specific types of trials. Some data points were not fully available for every patient.

We also need more time to see long-term effects. The follow-up period was about one year. Longer studies are still needed.

Doctors are now updating their guidelines based on this. They recommend offering exercise rehab to all heart patients.

More research will continue to refine these programs. We want to make sure every patient gets the right support.

The goal is to help you live longer and better. Exercise is a powerful tool in that journey. Talk to your care team about your next steps.

Study Details

Study typeMeta analysis
Sample sizen = 677
EvidenceLevel 1
Follow-up12.0 mo
PublishedApr 2026
View Original Abstract ↓
AIMS: The effectiveness of exercise-based cardiac rehabilitation (ExCR) for coronary heart disease (CHD) has been debated during the past decade. The objectives of the Cardiac Rehabilitation Meta-Analysis of Trials in people with CHD using individual participant data (IPD) (CaReMATCH) study were to (i) provide contemporary estimates on the effectiveness of ExCR for CHD and (ii) examine potential differential effects of ExCR across subgroups. METHODS AND RESULTS: Individual participant data from randomized controlled trials comparing ExCR with no ExCR controls were pooled. To reflect contemporary ExCR practice, trials had to be published since 2010. The outcomes of all-cause and cardiovascular disease (CVD)-related mortality and hospitalization and health-related quality of life (HRQoL) were analysed. From 30 eligible trials (10 677 participants), IPD were obtained from eight trials (4975 participants, 93.5% post-myocardial infarction). Compared with controls, participation in ExCR resulted in a lower risk for all-cause [hazard ratio (HR) 0.68, 95% confidence interval (CI): 0.53, 0.87] and CVD-related hospitalization (HR 0.62, 95% CI: 0.47, 0.83) and higher HRQoL up to 12 months of follow-up (mean difference in utility index: 0.032, 95% CI: 0.003, 0.061). No differences were found in all-cause and CVD mortality (HR 0.99, 95% CI: 0.74, 1.32; HR 0.80, 95% CI: 0.32, 2.04, respectively). Subgroup analyses showed stronger improvements of HRQoL with ExCR in people with lower HRQoL and lower education level and larger reductions in hospitalization risk in those with a lower left ventricular ejection fraction, lower baseline exercise capacity, beta-blockers use, and with a previous history of CVD. No other subgroup effects were observed. CONCLUSION: Our IPD meta-analysis, reflecting trials published since 2010, highlighted that contemporary ExCR is effective in reducing risk of hospitalization and improving HRQoL in those with CHD. Importantly, we reveal treatment benefits to be robust and consistent across most participant subgroups. Together, these data support the class I recommendation of international clinical guidelines that ExCR should be offered to all people with CHD. REGISTRATION: PROSPERO: CRD42020204988.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.